Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Feb 9, 2023
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Award
Employee Stock Option (right to buy)
2023-02-07+135,000→ 135,000 totalExercise: $7.20Exp: 2033-02-06→ Common Stock (135,000 underlying)
Footnotes (1)
- [F1]The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.